PDF(1704 KB)
PDF(1704 KB)
PDF(1704 KB)
儿童EBV阳性噬血细胞综合征的遗传分析及其与Th1/Th2细胞因子的关系
A genetic analysis of children with Epstein-Barr virus-positive hemophagocytic lymphohistiocytosis and its association with T-helper type 1/T-helper type 2 cytokines
目的 探讨遗传变异对EBV阳性噬血细胞综合征（HLH）患儿预后的影响及其与细胞因子的关系。方法 选取81例EBV阳性且已进行相关基因测序的HLH患儿，根据有无基因突变分为无突变组（n=35）和突变组（n=46），再根据基因突变方式分为单杂合突变（SHM）亚组、双杂合突变（DHM）亚组和纯合或复合杂合突变（H-CHM）亚组。测定各组患儿血清细胞因子水平，分析其与HLH基因突变的关系。结果 UNC13D基因突变出现频率最高（13/46，28%）。STXBP2 c.575G > A （p.R192H）和UNC13D c.604C > A （p.L202M）基因突变首次被报道，均判定为“可能致病的”。突变组TNF-α水平高于无突变组，IFN-γ水平低于无突变组（P < 0.05）。DHM亚组IL-4水平高于无突变组，H-CHM亚组IL-4水平低于DHM组（P < 0.0083）。H-CHM亚组的1年总生存率（39%±15%）低于无突变组、SHM亚组和DHM亚组（分别为85%±6%、86%±7%和91%±9%，P=0.001）。结论 具有基因突变的HLH患儿IFN-γ水平显著降低；H-CHM患儿的预后较差，而其他突变对其预后影响不显著，这可能有助于医生进行临床决策。
Objective To study the effect of genetic variation on the prognosis of children with Epstein-Barr virus (EBV)-positive hemophagocytic lymphohistiocytosis (HLH) and its association with cytokines. Methods A total of 81 EBV-positive HLH children who received the sequencing of related genes were enrolled. According to the results of gene detection, they were divided into a non-mutation group and a mutation group. According to the pattern of gene mutation, the mutation group was further divided into three subgroups:single heterozygous mutation (SHM), double heterozygous mutation (DHM), and homozygous or compound heterozygous mutation (H-CHM). The serum levels of cytokines were measured and their association with HLH gene mutations was analyzed. Results UNC13D gene mutation had the highest frequency (13/46, 28%). The STXBP2 c.575G > A(p.R192H) and UNC13D c.604C > A(p.L202M) mutations (likely pathogenic) were reported for the first time. The mutation group had a significantly higher level of tumor necrosis factor alpha (TNF-α) than the non-mutation group, while it had a significantly lower level of interferon gamma (IFN-γ) than the non-mutation group (P < 0.05). The IL-4 level of the DHM subgroup was higher than that of the non-mutation group, while the IL-4 level of the H-CHM subgroup was lower than that of the DHM group (P < 0.0083). The H-CHM subgroup had a significantly lower 1-year overall survival rate than the non-mutation group, the SHM subgroup, and the DHM subgroup (39%±15% vs 85%±6%/86%±7%/91%±9%, P=0.001). Conclusions There is a significant reduction in IFN-γ level in the mutation group. Children with homozygous or compound heterozygous mutation tend to have poorer prognosis, while other mutations do not have a significant impact on prognosis.
Hemophagocytic lymphohistiocytosis / Gene mutation / Cytokine / Child
[1] Janka GE, Lehmberg K. Hemophagocytic syndromes-an update[J]. Blood Rev, 2014, 28(4):135-142.
[2] Xu XJ, Wang HS, Ju XL, et al. Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China:a retrospective multicenter study[J]. Pediatr Blood Cancer, 2017, 64(4):e26264.
[3] Ishii E. Hemophagocytic lymphohistiocytosis in children:pathogenesis and treatment[J]. Front Pediatr, 2016, 4:47.
[4] Klutts JS, Ford BA, Perez NR, et al. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns[J]. J Clin Microbiol, 2009, 47(10):3204-3210.
[5] Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH[J]. Blood, 2011, 118(22):5794-5798.
[6] Palterer B, Brugnolo F, Sieni E, et al. Neuromyelitis optica, atypical hemophagocytic lymphohistiocytosis and heterozygous perforin A91V mutation[J]. J Neuroimmunol, 2017, 311:10-13.
[7] Zhang M, Bracaglia C, Prencipe G, et al. A heterozygous RAB27A mutation associated with delayed cytolytic granule polarization and hemophagocytic lymphohistiocytosis[J]. J Immunol, 2016, 196(6):2492-2503.
[8] Henter JI, Horne A, Aricó M, et al. HLH-2004:diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2):124-131.
[9] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants:a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5):405-424.
[10] Tang Y, Xu X, Song H, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome[J]. Br J Haematol, 2008, 143(1):84-91.
[11] Meeths M, Entesarian M, Al-Herz W, et al. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2[J]. Blood, 2010, 116(15):2635-2643.
[12] Zhao M, Kanegane H, Kobayashi C, et al. Early and rapid detection of X-linked lymphoproliferative syndrome with SH2D1A mutations by flow cytometry[J]. Cytometry B Clin Cytom, 2011, 80(1):8-13.
[13] Tesi B, Lagerstedt-Robinson K, Chiang SC, et al. Targeted high-throughput sequencing for genetic diagnostics of hemophagocytic lymphohistiocytosis[J]. Genome Med, 2015, 7:130.
[14] Liu D, Hu X, Jiang X, et al. Characterization of a novel splicing mutation in UNC13D gene through amplicon sequencing:a case report on HLH[J]. BMC Med Genet, 2017, 18(1):135.
[15] Kobayashi Y, Salih HM, Kajiume T, et al. Successful treatment with liposteroid followed by reduced intensity stem cell transplantation in an infant with perforin deficiency presenting with hemophagocytic lymphohistiocytosis[J]. J Pediatr Hematol Oncol, 2007, 29(3):178-182.
[16] Rubin TS, Zhang K, Gifford C, et al. Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH[J]. Blood, 2017, 129(22):2993-2999.
[17] Tothova Z, Berliner N. Hemophagocytic syndrome and critical illness:new insights into diagnosis and management[J]. J Intensive Care Med, 2015, 30(7):401-412.
[18] Marsh RA, Haddad E. How I treat primary haemophagocytic lymphohistiocytosis[J]. Br J Haematol, 2018, 182(2):185-199.
[19] Bittremieux W, Tabb DL, Impens F, et al. Quality control in mass spectrometry-based proteomics[J]. Mass Spectrom Rev, 2018, 37(5):697-711.
[20] Chinn IK, Eckstein OS, Peckham-Gregory EC, et al. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis[J]. Blood, 2018, 132(1):89-100.
国家自然科学基金（81770202）；浙江省自然科学基金重点项目（LZ12H08001）。
